Details for Patent: 8,648,037
✉ Email this page to a colleague
Which drugs does patent 8,648,037 protect, and when does it expire?
Patent 8,648,037 protects MAVYRET and is included in two NDAs.
Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has eighty patent family members in forty-one countries.
Summary for Patent: 8,648,037
| Title: | Macrocyclic proline derived HCV serine protease inhibitors |
| Abstract: | The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. |
| Inventor(s): | Or; Yat Sun (Watertown, MA), Ma; Jun (Belmont, MA), Wang; Guoqiang (Belmont, MA), Long; Jiang (Wayland, MA), Wang; Bin (Brookline, MA) |
| Assignee: | Enanta Pharmaceuticals, Inc. (Watertown, MA) |
| Application Number: | 13/237,120 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,648,037
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,648,037
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 083052 | ⤷ Try a Trial | |||
| Argentina | 116002 | ⤷ Try a Trial | |||
| Argentina | 118222 | ⤷ Try a Trial | |||
| Australia | 2011305695 | ⤷ Try a Trial | |||
| Australia | 2016204491 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
